Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01005329
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:59.228764+00:00
Published At
2014-02-24T00:00:00+00:00
Record Updated At
2018-03-15
Results Posted At
2014-02-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Stage IA Uterine Corpus Cancer AJCC v7", "Stage IB Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-03-15"
protocolSection.identificationModule.nctId
"NCT01005329"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2014-02-24"

Study condition terms

  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Adenosquamous Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage IA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage II Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.